文献速递肥胖与代谢综合征糖尿病

司美拉诺肽对Bardet-Biedl综合征患者代谢综合征风险的影响

Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究基于一项3期研究(NCT03746522),对Bardet-Biedl综合征(BBS)患者计算基于体质指数(BMI)的MetS-Z-BMI评分,评估代谢综合征严重程度及对黑皮质素-4受体激动剂司美拉诺肽治疗的反应。32例入组患者中22例可评估,第52周MetS-Z-BMI评分平均(SD)降低0.34(0.62),达成预设体重阈值者降幅大于未达成者,提示司美拉诺肽可能降低BBS患者的代谢综合征严重程度及未来肥胖相关合并症风险。

要点

  • 32例入组患者中22例可评估MetS-Z-BMI评分,基线平均(SD)为1.1(0.5)。
  • 第52周MetS-Z-BMI评分平均(SD)降低0.34(0.62)。
  • 达成预设体重阈值者第52周MetS-Z-BMI评分变化为-0.64(0.54),未达成者为0.08(0.47),P = .0043。

核心结论

  • 52周司美拉诺肽治疗后观察到MetS-Z-BMI评分降低,提示司美拉诺肽可能降低BBS患者的代谢综合征严重程度及未来肥胖相关合并症风险。

研究设计与样本

  • 一项3期研究(NCT03746522)中,所有具备计算MetS-Z-BMI评分所需数据的司美拉诺肽治疗患者被纳入。
  • 32例患者入组,其中22例的MetS-Z-BMI评分可评估。
  • 在基线及第52周测定平均MetS-Z-BMI评分,并按性别、年龄、基因型及对司美拉诺肽的反应进行亚组分析。

主要发现

  • 全部患者基线MetS-Z-BMI评分平均(SD)为1.1(0.5)。
  • 成人基线未来心血管疾病或2型糖尿病的平均(SD)比值比分别为3.1(1.5)和3.7(1.7),儿童患者分别为10.2(4.7)和2.8(1.3)。
  • 第52周MetS-Z-BMI评分平均(SD)降低0.34(0.62)。
  • 第52周达成预设体重阈值(年龄≥18岁者体重下降≥10%,年龄<18岁者BMI Z评分降低≥0.3分)者MetS-Z-BMI评分变化平均(SD)为-0.64(0.54),未达成者为0.08(0.47),P = .0043。
  • 其他亚组比较未观察到显著差异。

关键数值与推荐

  • MetS-Z-BMI评分基于体质指数(BMI)计算,用于判定代谢综合征严重程度。
  • 第52周达成体重下降≥10%(年龄≥18岁)或BMI Z评分降低≥0.3分(年龄<18岁)者与未达成者的MetS-Z-BMI评分变化差异P = .0043。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Bardet-Biedl syndrome (BBS) is a rare genetic disease associated with disruptions in melanocortin-4 receptor pathway signaling that can contribute to increased risk for metabolic syndrome and obesity-related comorbidities. OBJECTIVE: Here, MetS-Z-BMI scores, a continuous measure based on body mass index (BMI), were calculated to determine metabolic syndrome severity and response to treatment with the melanocortin-4 receptor agonist setmelanotide in BBS. METHODS: All patients from a phase 3 study (NCT03746522) of setmelanotide with data required for the calculation of MetS-Z-BMI scores were included. Mean MetS-Z-BMI score was determined at baseline and Week 52; subgroup analyses were conducted by sex, age, genotype, and response to setmelanotide. RESULTS: MetS-Z-BMI scores were evaluable for 22 of 32 patients enrolled. Baseline mean (SD) MetS-Z-BMI score across patients was 1.1 (0.5); baseline mean (SD) odds ratios of future cardiovascular disease or type 2 diabetes were 3.1 (1.5) and 3.7 (1.7), respectively, for adults and 10.2 (4.7) and 2.8 (1.3), respectively, for pediatric patients. Overall, mean (SD) MetS-Z-BMI score at Week 52 was reduced by 0.34 (0.62). Mean (SD) MetS-Z-BMI scores significantly differed depending on achievement of predetermined weight-based thresholds of ≥10% weight loss (patients aged ≥18 years) or ≥0.3-point reduction in BMI Z score (patients aged <18 years) at Week 52 (achievers, -0.64 [0.54]; nonachievers, 0.08 [0.47]; P = .0043). No significant difference was observed with other subgroup comparisons. CONCLUSION: MetS-Z-BMI score reductions were observed after 52 weeks of treatment, suggesting that setmelanotide may decrease metabolic syndrome severity and risk of future obesity-related comorbidities in those with BBS.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Haqq AM, Poitou C, Chung WK, et al. Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. J Clin Endocrinol Metab. 2025. PMID: 39919037. doi:10.1210/clinem/dgaf079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。